Resultats de la cerca - Charles D. Blanke

Refinar resultats
  1. 1
    Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation [letter]

    Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation [letter] per Robert Hromas, Kenneth Cornetta, Edward F. Srour, Charles D. Blanke, ER Broun

    Publicat 1994
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Oxaliplatin: Hohe Aktivität in allen Stadien des Kolonkarzinoms

    Oxaliplatin: Hohe Aktivität in allen Stadien des Kolonkarzinoms per Paulo M. Hoff, Leonard B. Saltz, Charles D. Blanke, Eric van Custem

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

    Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials per Joseph M. Unger, Charles D. Blanke, Michael LeBlanc, Dawn L. Hershman

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic

    Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic per Joseph M. Unger, Hong Xiao, Michael LeBlanc, Dawn L. Hershman, Charles D. Blanke

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Characterizing 18 Years of the Death With Dignity Act in Oregon

    Characterizing 18 Years of the Death With Dignity Act in Oregon per Charles D. Blanke, Michael LeBlanc, Dawn L. Hershman, Lee M. Ellis, Frank L. Meyskens

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)

    Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415) per Philip J. Gold, Bryan Goldman, Syma Iqbal, Lawrence P. Leichman, Wu Zhang, Heinz‐Josef Lenz, Charles D. Blanke

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

    Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors per George D. Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D. Blanke, Heikki Joensuu, Margaret von Mehren

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies

    A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies per Patricia A. Deverka, Rick Bangs, Karma L. Kreizenbeck, Deborah M Delaney, Dawn L. Hershman, Charles D. Blanke, Scott D. Ramsey

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

    Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer per Syma Iqbal, Bryan Goldman, Cecilia M. Fenoglio‐Preiser, Heinz‐Josef Lenz, W. Zhang, K. D. Danenberg, Stephen Shibata, Charles D. Blanke

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Let’s Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine

    Let’s Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine per Laura Tenner, Fay J. Hlubocky, Charles D. Blanke, Thomas W. LeBlanc, Jonathan M. Marron, Molly McGinnis, Rebecca Spence, Lynne P. Taylor

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Trends in Medical Aid in Dying in Oregon and Washington

    Trends in Medical Aid in Dying in Oregon and Washington per Luai Al Rabadi, Michael LeBlanc, Taylor Bucy, Lee M. Ellis, Dawn L. Hershman, Frank L. Meyskens, Lynne P. Taylor, Charles D. Blanke

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

    Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414) per Michael Tomblyn, Bryan Goldman, Charles R. Thomas, Jacqueline Benedetti, Heinz‐Josef Lenz, Vivek Mehta, Thaddeus Beeker, Philip J. Gold, James L. Abbruzzese, Charles D. Blanke

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

    S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma per Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel, Syma Iqbal, I-Y Gong, Kenneth C. Micetich, Omar Kayaleh, H-J Lenz, Charles D. Blanke

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

    SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma per Anthony B. El-Khoueiry, Cathryn Rankin, Edgar Ben‐Josef, Heinz‐Josef Lenz, Philip J. Gold, Robert D. Hamilton, Rangaswamy Govindarajan, Cathy Eng, Charles D. Blanke

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

    Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer per Kathy D. Miller, Joel Picus, Charles D. Blanke, William J. John, Jeffrey W. Clark, Lawrence N. Shulman, D. Thornton, Eric K. Rowinsky, Patrick J. Loehrer

    Publicat 2000
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials

    Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials per Charles D. Blanke, Brian M. Bot, David M. Thomas, Archie Bleyer, Claus-Henning Köhne, Michel Seymour, Aimery de Gramont, Richard M. Goldberg, Daniel J. Sargent

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

    Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) per Robert P. Whitehead, Cathryn Rankin, Paulo M. Hoff, Philip J. Gold, Kevin G. Billingsley, Robert Chapman, Lucas Wong, John H. Ward, James L. Abbruzzese, Charles D. Blanke

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal

    End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal per Carmen J. Allegra, Charles D. Blanke, Marc Buyse, Richard M. Goldberg, Axel Grothey, Neal J. Meropol, Leonard B. Saltz, Alan P. Venook, Greg Yothers, Daniel J. Sargent

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  19. 19
    Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

    Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gem... per Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Heinz‐Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Takeru Wakatsuki, Syma Iqbal, Rakesh Gaur, Jacqueline Benedetti, Charles D. Blanke

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (<scp>S</scp>1005)

    Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative... per Ramesh K. Ramanathan, Shannon McDonough, Hagen F. Kennecke, Syma Iqbal, Joaquina Baranda, Tara Elisabeth Seery, Howard J. Lim, Aram F. Hezel, Gina M. Vaccaro, Charles D. Blanke

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: